Rosemarie Tully Appointed COO of Neuromod Devices Limited

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Today Dublin based Neuromod Devices Limited announced the appointment of Rosemarie Tully as the new Chief Operating Officer (COO). Ms. Tully most recently held the role of Chief Business Officer, responsible for business development, corporate, and commercial strategy.

In addition to her current responsibilities for corporate development and strategy, Ms. Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms. Tully will continue to report to Dr. Ross O’Neill, Chief Executive Officer of Neuromod.

As COO, Ms. Tully will play a key role in supporting Neuromod’s accelerated growth phase as it transitions from a research and development organization to a large-scale manufacturing organization, supporting the commercialization of the Company’s tinnitus treatment device, Lenire®. As COO, Ms. Tully’s key short-term focus will be scaling up manufacturing capacity of the Lenire® device to meet anticipated European demand; and implementing regulatory strategy required to support market entry into the United States.

Commenting on the announcement, Dr. Ross O Neill, CEO of Neuromod Devices said: “I am delighted to announce Rosemarie’s appointment as Chief Operating Officer. Rosemarie’s broad skill set and extensive international experience in senior leadership roles in the Pharma sector have been crucial to the development of Neuromod, since she joined the company in 2018. Rosemarie has also delivered key commercial initiatives like the successful launch of our Lenire® brand in Ireland and Germany. As COO she will continue to support myself and our newly appointed Chief Commercial Officer, Florian Elsäßer as the roll-out of our commercial strategy accelerates in key markets”.

Ms. Tully is a registered pharmacist, with more than 20 years of industry experience including senior roles in corporate development and strategy at Sigmoid Pharma (now Sublimity Therapeutics), Elan Corporation (now Perrigo), as well as strategy consulting experience at McKinsey & Company. Ms. Tully earned her BSc (Pharm) at Trinity College Dublin, Ireland, and an MBA from INSEAD, France.

 

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles